MetaVia reports statistically significant 1.47 mg/dL uric acid reduction
MetaVia announced a placebo-adjusted reduction in uric acid levels in a Phase 1 trial, reinforcing data on its and incretin-based treatment’s potential for liver-related cardiometabolic diseases, enhancing its profile for future market interest.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed